Immunome CFO Max Rosett Executes $1.09M Stock Sale Under Pre-Arranged Trading Plan
Immunome Inc. (NASDAQ: IMNM) Chief Financial Officer Max Rosett executed a sale of 60,000 shares on June 15, 2026, generating $1,093,800 under a Rule 10b5-1 plan adopted in late 2025. The transaction followed the immediate exercise of 60,000 vested stock options at $1.05 per share. This activity occurs against a backdrop of significant share apprec…